News | July 27, 2012

Elekta Grant to Support Pediatric Cancer Research in Spain

€32,000 bequest given to Madrid Hospital Foundation for research at Madrid’s Montepríncipe Hospital

July 27, 2012 — To support research exploring childhood cancers, Elekta has given a €32,000 ($40,000) grant to Madrid Hospital Foundation’s pediatric oncology program at the Madrid Montepríncipe Hospital's pediatric oncology and hematology unit. The donation was collected at a charity party held in conjunction with the 2012 Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) in Barcelona. The foundation’s pediatric oncology research programs focus on increasing the understanding of cancer in children, and on improving treatment methods and the patient’s quality of life.

“Because cancer occurs more often in adults than in children, most of today’s technological developments in radiation therapy focus on adult patients and their needs,” said Tomas Puusepp, president and CEO of Elekta. “To address this imbalance, we are pleased to support the efforts of worthy pediatric cancer research programs such as the foundation’s pediatric oncology program. Elekta’s own efforts are aimed at adapting radiation therapy treatments to children, such as developing more suitable immobilization devices and imaging strategies, and by studying how to adjust doses for pediatric patients. To that end, we recently created the Elekta Pediatric Research Group, whose mission is to identify, develop and adapt products to treat childhood cancer."

Elekta’s products are currently not approved for use on children.

For more information: www.elekta.com

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve